Femasys (FEMY) Net Income towards Common Stockholders (2020 - 2025)
Femasys' (FEMY) quarterly Net Income towards Common Stockholders came in at -$4.6 million in Q2 2025, up 2.11% YoY from -$4.5 million in Q2 2024, and up 22.23% on a QoQ basis from -$5.9 million in Q1 2025.
Femasys (FEMY) Net Income towards Common Stockholders (2020 - 2025) Analysis & Trends
Femasys (FEMY) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$4.6 million in Q2 2025.
- Quarterly Net Income towards Common Stockholders rose 2.11% year-over-year to -$4.6 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was -$4.6 million (up 78.28% YoY) and the FY2025 annual result came in at -$18.6 million, up 1.0% from the prior year.
- Net Income towards Common Stockholders improved to -$4.6 million in Q2 2025, from -$5.9 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.1 million in Q2 2021 to a low of -$5.9 million in Q1 2025.
- A 5-year average of -$3.5 million and a median of -$3.0 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders advanced 27.09% — and 2022, when it tumbled 143.21%.
- Tracing FEMY's Net Income towards Common Stockholders over 5 years: stood at -$2.4 million in 2021, then dropped by 22.38% to -$2.9 million in 2022, then sank by 52.39% to -$4.4 million in 2023, then dropped by 16.17% to -$5.1 million in 2024, then grew by 10.5% to -$4.6 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$4.6 million (Q2 2025), -$5.9 million (Q1 2025), and -$5.1 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 132.71 Bn | 127.50 Bn | 1.96 Bn | 823.20 Mn |
| 2 | Becton Dickinson | 51.57 Bn | 50.71 Bn | 2.32 Bn | 378.00 Mn |
| 3 | Alcon | 35.52 Bn | 34.17 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.28 Bn | 31.81 Bn | 861.22 Mn | 383.43 Mn |
| 5 | Medline | 27.86 Bn | 25.18 Bn | 2.22 Bn | 139.00 Mn |
| 6 | West Pharmaceutical Services | 25.15 Bn | 24.71 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Solventum | 15.31 Bn | 14.91 Bn | 1.29 Bn | 93.00 Mn |
| 8 | Cooper Companies | 14.86 Bn | 14.72 Bn | 735.40 Mn | -77.90 Mn |
| 9 | Baxter International | 13.63 Bn | 11.48 Bn | 1.03 Bn | 126.00 Mn |
| 10 | Femasys | 8.98 Mn | 7.54 Mn | 189,391.00 | -4.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -4.59 Mn |
| Mar 31, 2025 | -5.90 Mn |
| Dec 31, 2024 | -5.12 Mn |
| Sep 30, 2024 | -5.41 Mn |
| Jun 30, 2024 | -4.68 Mn |
| Mar 31, 2024 | -3.60 Mn |
| Dec 31, 2023 | -4.41 Mn |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | -2.89 Mn |
| Mar 31, 2023 | -2.95 Mn |
| Dec 31, 2022 | -2.89 Mn |
| Sep 30, 2022 | -2.98 Mn |
| Jun 30, 2022 | -2.63 Mn |
| Mar 31, 2022 | -2.88 Mn |
| Dec 31, 2021 | -2.36 Mn |
| Sep 30, 2021 | -2.26 Mn |
| Jun 30, 2021 | -1.08 Mn |
| Mar 31, 2021 | -1.83 Mn |
| Dec 31, 2020 | -1.66 Mn |
| Sep 30, 2020 | -1.57 Mn |